Target intelligence / Profile preview

Procollagen galactosyltransferase 1 (COLGALT1)

Target
COLGALT1
Molecular classification
Enzyme, Transferase, Glycosyltransferase
01

Overview

Procollagen galactosyltransferase 1 (COLGALT1), also known as GLT25D1, is a key endoplasmic reticulum-resident enzyme belonging to the glycosyltransferase 25 family. It catalyzes the transfer of beta-galactose to specific hydroxylysine residues of procollagen, a critical early step in collagen post-translational modification and O-glycosylation. This modification is essential for proper collagen folding, triple-helix formation, secretion, and subsequent extracellular matrix assembly. Mutations in the COLGALT1 gene lead to underglycosylated collagen and are associated with brain small vessel disease 3 (BSVD3), characterized by vascular fragility, porencephaly, and intracranial hemorrhage. Additionally, altered expression of COLGALT1 has been implicated in fibrosis and the progression of certain cancers, such as kidney renal clear cell carcinoma, where it correlates with poor prognosis and an immunosuppressive tumor microenvironment. Currently, there are no approved drugs or active clinical candidates targeting this enzyme, but it represents an emerging biomarker and potential therapeutic target for modulating collagen-related pathologies.

Other names
Collagen beta(1-O)galactosyltransferase 1Glycosyltransferase 25 family member 1Hydroxylysine galactosyltransferase 1GLT25D1ColGalT 1BSVD3
02

Mechanism of action

No approved drugs or established small-molecule inhibitors target this enzyme. In a therapeutic context, potential mechanisms would involve inhibition of its galactosyltransferase activity to modulate collagen deposition in fibrosis or cancer, or gene therapy/enzyme replacement to restore activity in genetic deficiencies.

03

Biological functions

Protein O-linked glycosylationCollagen fibril organizationCollagen biosynthesisPost-translational modification
04

Disease associations

Brain small vessel disease 3PorencephalyCancerFibrosisConnective tissue disorder
05

Safety considerations

Vascular fragilityIntracranial hemorrhagePorencephalyConnective tissue defectsAbnormal collagen fibril assembly
06

Biomarkers

COLGALT1 expression levelCOLGALT1 mutation statusCollagen glycosylation status

Beyond the preview

Go deeper on Procollagen galactosyltransferase 1 (COLGALT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Procollagen galactosyltransferase 1 (COLGALT1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call